ADIR LUDIN

Allopathic & Osteopathic Physicians|Radiology|Radiation Oncology CLEVELAND, OH NPI 1679653166

General Payments — all program years on this page

$2,388.89

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 92
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $549.73 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $549.7319

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $200.573
2019 $147.034
2020 $110.936
2021 $430.1321
2022 $457.1117
2023 $493.3922
2024 $549.7319

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086160692 Bayer Healthcare Pharmaceuticals Inc. $18.47 10/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086167800 Bayer Healthcare Pharmaceuticals Inc. $17.44 07/31/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086181239 Bayer Healthcare Pharmaceuticals Inc. $16.81 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086225600 Bayer Healthcare Pharmaceuticals Inc. $118.30 08/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087150064 Novartis Pharmaceuticals Corporation $24.64 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104729747 AstraZeneca Pharmaceuticals LP $13.81 03/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1128507762 PROGENICS PHARMACEUTICALS, INC. $13.18 08/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1128510639 PROGENICS PHARMACEUTICALS, INC. $16.33 06/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1128512715 PROGENICS PHARMACEUTICALS, INC. $16.04 10/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1128514985 PROGENICS PHARMACEUTICALS, INC. $17.95 01/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142084308 Teleflex LLC $25.53 05/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147791236 Blue Earth Diagnostics Limited $14.79 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147791247 Blue Earth Diagnostics Limited $13.34 02/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147791383 Blue Earth Diagnostics Limited $16.18 08/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147791427 Blue Earth Diagnostics Limited $16.60 09/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147791472 Blue Earth Diagnostics Limited $22.61 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148883908 Sumitomo Pharma America, Inc. $15.46 03/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1148883910 Sumitomo Pharma America, Inc. $13.93 11/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1154296457 BIOPROTECT MEDICAL, INC. $138.32 07/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.